Opinion

Video

Dyskinesia: Importance of Giving Patients More Good “On- Time" In Parkinson’s Disease

Author(s):

Stuart H. Isaacson, MD, FAAN,Rajesh Pahwa, MD

Drs Isaacson, Pahwa, and Gupta discuss the management of dyskinesia and providing good ON time in Parkinson’s disease, sharing practical tips for early identification and treatment of dyskinesia, as well as their experience with current treatments.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Timecodes:

      1:28 Defining ON time in PD

      4:50 Dyskinesia experience

      8:00 Tremor and dyskinesia

      13:30 Dyskinesia and QoL

      16:00 Dyskinesia and OFF

      19:30 Tailoring treatment

      22:00 Amantadine DR/ER

      29:00 Amantadine candidates

      Related Videos
      Insights on Quanterix Simoa Assay to Diagnose Alzheimer Disease: Mark Roskey, PhD
      Insights on Quanterix Simoa Assay to Diagnose Alzheimer Disease: Mark Roskey, PhD
      Patients’ Experience With Foscarbidopa/Foslevodopa CSCI for Treatment of Parkinson Disease
      Patients’ Experience With Foscarbidopa/Foslevodopa CSCI for Treatment of Parkinson Disease
      Clinical Data With Foscarbidopa/Foslevodopa CSCI in Parkinson Disease
      Clinical Data With Foscarbidopa/Foslevodopa CSCI in Parkinson Disease
      5 experts in this video
      Adjunctive Treatments and Apomorphine for Treatment of Parkinson Disease
      5 experts in this video
      Advanced Treatment Options in Parkinson Disease
      Fernando L. Pagan, MD
      Personalizing Treatment Plans for Patients With PD
      Fernando L. Pagan, MD
      Patient Insights and Evolving Treatment Combos in PD
      Cheryl Kyinn, PA-C
      Technological Advances Leading the Future of Parkinson Care: Cheryl Kyinn, PA-C
      Fernando L. Pagan, MD
      The Growing Role of AI in Neurology
      Continuous Subcutaneous Delivery Systems: Foscarbidopa/Foslevodopa for Treatment of Parkinson Disease
      Continuous Subcutaneous Delivery Systems: Foscarbidopa/Foslevodopa for Treatment of Parkinson Disease
      Related Content
      Gene Therapy AAV-GAD Gains Regenerative Medicine Advanced Therapy Designation as Potential Parkinson Treatment
      May 12th 2025

      Gene Therapy AAV-GAD Gains Regenerative Medicine Advanced Therapy Designation as Potential Parkinson Treatment

      Marco Meglio
      Multisymptomatic Care in Parkinson's Disease
      September 4th 2024

      Multisymptomatic Care in Parkinson's Disease

      Stuart H. Isaacson, MD, FAAN Rajesh Pahwa, MD Jennifer G. Goldman, MD, MS
      Subthalamic Focused Ultrasound Outperforms Ventral Intermediate Thalamotomy in Sustained Parkinson Disease Tremor Control
      May 7th 2025

      Subthalamic Focused Ultrasound Outperforms Ventral Intermediate Thalamotomy in Sustained Parkinson Disease Tremor Control

      Marco Meglio
      Sleeping Around the Podcast × NeurologyLive: Candidate Biomarkers to Detect REM Sleep Behavior Disorder in Parkinson Disease
      April 9th 2024

      Sleeping Around the Podcast × NeurologyLive: Candidate Biomarkers to Detect REM Sleep Behavior Disorder in Parkinson Disease

      Anne Marie Morse, DO, FAASM NeurologyLive® Staff
      Investigating Therapeutic Potential of Gene Therapy AB-1005 in Moderate Parkinson Disease: The REGENERATE-PD Trial
      April 30th 2025

      Investigating Therapeutic Potential of Gene Therapy AB-1005 in Moderate Parkinson Disease: The REGENERATE-PD Trial

      Isabella Ciccone, MPH
      Valbenazine Safe and Effective for Long-Term Treatment of Tardive Dyskinesia in Elders
      April 29th 2025

      Valbenazine Safe and Effective for Long-Term Treatment of Tardive Dyskinesia in Elders

      Marco Meglio
      © 2025 MJH Life Sciences

      All rights reserved.